Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GRAIL, Inc. - Common Stock (NQ:GRAL)

58.16 -13.52 (-18.86%)
Streaming Delayed Price Updated: 10:51 AM EDT, Jun 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GRAIL, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Which stocks are moving before the opening bell on Friday? ↗
Via Chartmill
News headline image
Why Is GRAL Stock Down Today? Analysts Lower Targets After UK Trial Setback But Call Selloff Overdone ↗
Baird analyst Catherine Ramsey Schulte slashed the price target on Grail to $82 from $113 while reiterating an ‘Outperform’ rating. 
Via Stocktwits
News headline image
Why Grail Stock Is Sinking Friday ↗
GRAIL (NASDAQ: GRAL) shares plunged after the NHS-Galleri trial failed to meet its primary endpoint. Explore the trial results. 
Via Benzinga
GRAIL INC (NASDAQ:GRAL) Plummets 47% Despite Narrower-Than-Expected Q4 Loss ↗
Via Chartmill
News headline image
Earnings Scheduled For November 12, 2025 ↗
 
Via Benzinga
News headline image
Nasdaq, S&P 500 Futures Rise Before PCE Report, Likely Tariff Ruling: Why NVDA, TSLA, GOOGL, IBRX, APP, GRAL Are On Traders' Radar Today ↗
Data from Stocktwits indicated retail sentiment on QQQ turned bearish amid elevated message volume. 
Via Stocktwits
Topics ETFs Economy Government
News headline image
Grail Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
From Johnson Fistel, PLLP
Via Business Wire
News headline image
GRAL Stock Slumps After Hours As Trial For Cancer Test Fails To Show Reduction In Late-Stage Diagnoses ↗
The trial did not show a statistically significant reduction in Stage III-IV cancer diagnoses, the company said. 
Via Stocktwits
Topics Artificial Intelligence Death
Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
Via Chartmill
News headline image
Here's Why This Exciting Healthcare Stock Popped 13% Today ↗
Investors are getting excited by the prospects for Grail's Galleri test in 2026. 
Via The Motley Fool
News headline image
GRAIL Surges as Canaccord Genuity Sets Ambitious $105 Price Target Following Robust 2025 Growth
In a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an... 
Via MarketMinute
News headline image
Small-Cap Standouts: These 3 Stocks Rose Over 300% in 2025 ↗
Via MarketBeat
News headline image
Here's Why Grail Soared, Again, in November ↗
A combination of operational improvements and developments at its key rival bolstered the stock recently. 
Via The Motley Fool
News headline image
Why GRAIL Stock Could Be Biotech’s Next Big Breakout ↗
Via MarketBeat
News headline image
Why Grail Stock Zoomed Nearly 7% Higher on Monday ↗
The company has significant potential with its comprehensive cancer test. 
Via The Motley Fool
News headline image
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
GRAIL (GRAL) Q3 2025 Earnings Call Transcript ↗
GRAIL (GRAL) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
GRAIL INC (NASDAQ:GRAL) Q3 2025 Earnings: Tops Revenue and EPS Estimates as Galleri Sales Climb ↗
GRAIL (GRAL) Q3 2025 earnings beat estimates on revenue and EPS, sending the stock higher. Strong growth for its Galleri cancer test drove the positive results. 
Via Chartmill
Topics Earnings
News headline image
Here's Why Grail Stock Exploded Higher by 55% in October ↗
The company demonstrated tangible progress on its path to profitability. 
Via The Motley Fool
News headline image
Grail Stock Is Up 80% Over the Past Month. Here's Why. ↗
This cancer detection test maker just got some great news. 
Via The Motley Fool
News headline image
Grail's CEO Sells 7,200 Shares for nearly $500,000 ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
Topics Artificial Intelligence
News headline image
Why Is GRAL Stock Rising Today? ↗
GRAIL plans to raise about $325 million through a private placement involving both new and existing institutional investors. 
Via Stocktwits
News headline image
Why Grail Stock Soared 14% Higher on Thursday ↗
The company is receiving a significant equity investment as a component of a collaboration agreement with a large business partner. 
Via The Motley Fool
News headline image
Enerpac Tool Group Posts Upbeat Results, Joins Praxis Precision Medicines, J B Hunt, Salesforce And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
This Cancer Detection Pioneer Is Worth a Look ↗
Multicancer detection tests are closing in on FDA approval and potentially major sales. 
Via The Motley Fool
News headline image
GRAIL INC (NASDAQ:GRAL) Reports Mixed Q2 2025 Earnings: Revenue Misses, Loss Narrows ↗
GRAIL Inc. (NASDAQ:GRAL) reported Q2 2025 results with revenue of $35.5M missing estimates, but a narrower EPS loss of -$3.18. Galleri test sales grew 21% YoY. Shares fell 2.6% post-earnings.... 
Via Chartmill
News headline image
Earnings Scheduled For August 12, 2025 ↗
 
Via Benzinga
News headline image
Wall Street Rises Ahead Of Fed, Payment Stocks Fall On Stablecoin Bill: What's Driving Markets Wednesday? ↗
U.S. stocks inched higher by midday Wednesday, as traders weighed geopolitical uncertainty and awaited the Federal Reserve's June policy decision. 
Via Benzinga
Topics Economy
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.